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Purpose: COPD is a condition with systemic effects of which peripheral muscle dysfunction is
a prominent contributor to exercise limitation, health related quality of life (HRQoL) impair-
ment, and is an independent predictor of morbidity and mortality. Pulmonary rehabilitation
(PR) is a successful strategy to improve exercise tolerance and HRQoL through the improve-
ment of muscle function in patients with stable COPD or early after severe exacerbations
of COPD (SECOPD). However, muscle function further deteriorates during SECOPD before early
PR programmes commence. We aimed to investigate the feasibility and efficacy of quadriceps
neuromuscular electrical stimulation (NMES) applied during a SECOPD to prevent muscle func-
tion deterioration.
Methods: We have conducted a pilot study in eleven COPD patients (FEV1 41.3  5.6 % pred)
admitted to hospital with a SECOPD. We randomly allocated one leg to receive NMES (once
a day for 14 days) with the other leg as a control (non-stimulated leg). We measured the
change in quadriceps maximal voluntary contraction (DQMVC) as the main outcome.
Results: Mean quadriceps muscle strength decreased in control legs (DQMVC 2.9  5.3 N,
p Z ns) but increased in the stimulated legs (DQMVC 19.2  6.1 N, p < 0.01). The difference
in DQMVC between groups was statistically significant (p < 0.05). The effect of NMES was
directly related to the stimulation intensity (
P
mA) applied throughout the 14 sessions
(r Z 0.76, p < 0.01). All patients tolerated NMES without any side effects.) 131 2429198; fax: þ44 (0) 131 242 6582.
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derangement during severe exacerbations of COPD and may be used to compliment early post-
exacerbation pulmonary rehabilitation.
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The natural course of Chronic Obstructive Pulmonary
Disease (COPD) is complicated by the development of
systemic consequences of the disease.1 Skeletal muscle
dysfunction, particularly of the limb muscles, is one of the
most prominent and extensively studied systemic effects2,3
and a major contributor to exercise limitation,4,5 health
related quality of life (HRQoL) impairment,5 health care
utilization increments6 and is an independent predictor of
morbidity and mortality,7 which is partly independent of
the severity of the airflow limitation.8,9
Pulmonary rehabilitation (PR) is a successful strategy to
improve exercise tolerance and HRQoL through the
improvement of muscle function in patients with stable
COPD10 or early after severe exacerbations of COPD
(SECOPD) (w30 days after a SECOPD).11 However, SECOPD
further impair muscle weakness during a SECOPD before
the implementation of early PR programmes,12 which
contributes to further deteriorate skeletal muscle
function.12
PR programmes during a SECOPD are difficult to imple-
ment due to the clinical condition of these patients, and
strategies avoiding respiratory system stress are needed.13
Neuromuscular electrical stimulation (NMES) is a muscle
training technique that has been used in diverse conditions,
such as stroke, orthopaedic surgery, chronic heart failure
and also in COPD14e16 incurring minimal stress to the
respiratory system.14,17 Moreover, it is relatively inexpen-
sive and patients can be trained to self-administer NMES
constituting an ideal strategy to prevent skeletal muscle
deterioration occurring during SECOPD.
The aim of this pilot study was to test the efficacy and
feasibility of a short NMES programme (14 consecutive days)
during SECOPD with the aim to prevent exacerbation
related skeletal muscle function (strength) deterioration in
COPD patients admitted to the hospital.
We hypothesises that NMES administered within the first
48 h after admission and for 14 consecutive days would be
feasible for patients with an exacerbation of COPD and
would prevent muscle function impairment secondary to
a SECOPD.QMVC
Leg 
randomization
QMVC
Figure 1 Study design. Patients were recruited within 48 h of
admission to the hospital with SECOPD. Muscle strength of both
quadriceps was measured and NMES was commenced in one leg
during 14 consecutive days, starting in hospital and continuing
at home. QMVC was measured again after 14 sessions and mean
difference between groups was compared.Methods
Study group
Eleven COPD patients (5 male), were recruited within 48 h
of admission to hospital due to a SECOPD. Patients had
a history compatible with COPD, at least 20 pack years of
smoking history and evidence of chronic airflow limitation
(post bronchodilator FEV1/FVC < 0.7, FEV1 < 80%predicted). All patients were on treatment with short- and
long-acting bronchodilators and inhaled corticosteroids and
three patients were on long term oxygen therapy (LTOT).
Exclusion criteria included: 1) Need of respiratory support
or admission to intensive care unit; 2) Any condition that
precluded a reliable muscle strength measurement (e.g.
knee arthritis); 3) Other conditions associated with myop-
athy; 4) Engaged in any PR program at the time of admis-
sion; 5) Any hospital admission or ECOPD within the
previous 3 months.
All admitted patients received standard treatment,
including nebulised bronchodilators, oxygen, oral or intra-
venous antibiotics and a 7e14 days course of oral prednis-
olone (30e40 mg daily).
All participants were informed of any risks and discom-
fort associated with the study, and written informed
consent was obtained. The study was approved by the
Lothian Regional Ethics Committee.
Study design
Maximal isometric voluntary contraction of both quadriceps
muscles (QMVC) was measured and the dominant leg was
randomly allocated to treatment with NMES or no stimula-
tion (control) for 14 consecutive days (1 session per day)
starting at the hospital and continuing at home after
discharge. The QMVC was assessed again 48 h after the last
NMES session (Fig. 1). A NMES protocol based on previous
studies was selected.14e17 NMES was administered trans-
cutaneously to the selected leg using an electrical stimu-
lator (ELPHA II 3000, Danmeter, DK) through two self-
Table 1 Patient characteristics.
Variable nZ11
Gender (F/M) 6/5
Age (years) 72.2  3.1
Height (m) 1.6  0.1
Weight (Kg) 61.3  4.3
BMI (Kg/m2) 23.2  1.3
FEV1 (%pred) 41.3  5.6
FVC (%pred) 76.9  4.7
FEV1/FVC (%) 40.7  4.1
QMVC (N) 215.2  21.8
QMVC (%pred) 65.6  3.8
BMIZ body mass index; FEV1Z forced expiratory volume in the
first second; FVC Z forced vital capacity; QMVC Z quadriceps
maximal voluntary contraction.
NMES in severe COPD exacerbations 1431adhering surface silver electrodes (Superior Silver 612SS,
Uni-Patch, MN, USA) placed longitudinally on the mid
aspect of the quadriceps (5 cm distal from the inguinal
ligament) and vastus medialis (5 cm proximal from the
patella). An asymmetrical bi-phase pulse wave, 400 ms
pulse duration, 50 Hz frequency, 8/20 s on/off cycle, in
30 min sessions was used. One session per day was applied.
During this session, patients were able to regulate the
intensity (mA) of the stimulation according to their
tolerance.
Patients received their first stimulation supervised
session after the randomization, within 48 h of admission,
starting with the maximum tolerated voltage and were
encouraged to raise the intensity during each consecutive
session thereafter. Subjects were instructed on how to use
the device and on electrode placement during the first 2
supervised sessions and were then supervised in one further
occasion during their admission. Once discharged from
hospital, patients continued to self-administer NMES until
the completion of 14 sessions. In order to guarantee the
compliance with the NMES programme, one extra session
was supervised at home. Patients were followed up by
telephone calls (on two occasions) throughout the program
and extra supervised sessions at the patient’s home were
added if needed. Patients were given a diary to collect
information on the maximal intensity used throughout each
individual NMES session. The battery power of each device
was measured before and after the period of 14 days of
NMES using a digital multimeter to reassure that the patient
was using the device appropriately during the 14 days
period of treatment.
Measurements
Anthropometric measurements
Body weight was measured to the nearest 0.1 kg with
a digital scale and height was measured to the nearest
0.5 cm with a stadiometer. Body mass index (BMI) was
calculated as the ratio of weight (in kilogrammes) to height
(in metres) squared.
Lung function
Post bronchodilators spirometry was measured one month
after the exacerbation when the patient was clinically
stable (Alpha Spirometer; Vitalograph, Buckingham, UK)
according to American Thoracic Society/European Respi-
ratory Society standards.
Muscle strength
As a recognised measurement of muscle function, quadri-
ceps muscle strength, was assessed using the maximal
isometric voluntary contraction technique (QMVC)
following a standardised technique.7,18 Briefly, patients
were measured while seated and secured in a purpose-built
chair, with hips and knees flexed at 90. To avoid effects on
the contra lateral leg, hips and chest were fixed to the chair
with a strap system and patients performed the QMVCmanoeuvre with their arms crossed in front of their chest. A
strain gauge (Chatillon K-MSC 500, AMETEK, FL, USA) was
attached to the back of the chair. An inextensible strap
placed around the subject’s ankle was firmly attached to
the dynamometer ensuring an isometric measurement.
Patients performed at least three sustained maximal
quadriceps contractions of between 4 and 6 s duration.
Maximal tension was assessed when the force elicited
reached a plateau, and a difference less than 10% between
manoeuvres was reached. The maximal effort was used for
analysis.
Statistical analysis
Results are described as mean  SEM and force units in
Newton (N), unless otherwise specified, QMVC percentage
of predicted values were calculated.19 Unpaired T-test was
used to analyze differences between groups. The level of
significance for all comparisons was set at p < 0.05. Total
amount of energy used throughout the program by each
subject was calculated as the sum of the maximal amount
(
P
mA) of each day and correlated with the gain in muscle
strength in the stimulated leg by Pearson’s correlation test.
Data were analyzed using the statistical package program
SPSS Version 17.0 (SPSS Inc, Chicago, Illinois, USA).Results
Anthropometric characteristics and pulmonary function
data of study subjects are depicted in Table 1. The patients
in general had severe COPD. Body composition (BMI) was
preserved and quadriceps muscle strength was below the
predicted values. After randomisation, seven dominant legs
were allocated to the NMES group, and 4 dominant legs
were allocated to the control group. There was no differ-
ence in QMVC at baseline between legs allocated to stim-
ulation (205.9  19.7 N) or control (206.5  22.6 N).
After 14 days of stimulation/control, QMVC increased by
19.2  6.1 N (8.4  2.4%), (p < 0.01) in the stimulated legs
whereas there was a decrease in muscle strength of
2.9  5.3 N (2.2  2.6%), (p Z ns) in control legs. The
1432 S. Giavedoni et al.differences in DQMVC between treatment and control was
statistically significant (p < 0.05) (Fig. 2A).
The changes in DQMVC of the stimulated leg as a func-
tion of DQMVC in the control leg show a clear effect in
favour of NMES (Fig. 2B).
The effect of NMES on muscle strength in the stimulated
leg was directly related to the amount of energy applied
(
P
mA) throughout the 14 days treatment (r Z 0.76,
p < 0.01) (Fig. 2C). There was a clear difference in the mA
tolerated by the male patients in comparison with the
females (Fig. 2D). Male subjects started with higher inten-
sity levels and were able to sustain higher increments in the
mA throughout the program, reaching higher total stimu-
lation energy levels by the end of the program. There was
no relationship between days in hospital and effects of NME
on QMVC. In addition, except for two patients that required
no visits after discharge, and one patient that was not
discharged during the 14 days of duration of the protocol,
all of the remaining patients received only one extra visit at
home. No patient required more than one extra visit at
home. There was no relationship between visit number and
the NMES effect.Discussion
This pilot study shows that a short NMES programme is
feasible and effective in preventing skeletal muscle func-
tion deterioration in COPD patients during SECOPD.NMES Control
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Figure 2 (A) Individual data of DQMVC (Newton) from both NME
DQMVC of stimulated leg as a function of DQMVC of the control leg s
correlation coefficient between change in muscle force (DQMVC) an
the stimulated legs (r Z 0.76, p < 0.01). (D) Mean and SEM (erro
female patients. Male subjects are represented as black closed cirSECOPD further impairs skeletal muscle function in COPD
patients with an impact on exercise capacity and physical
activity that is related to a higher hospital re-admission
risk.12 Early PR programmes are effective at improving
exercise tolerance through the improvement of muscle
function.11 However, skeletal muscle function deteriorates
during hospitalisations before the start of these pro-
grammes. Interventions aimed at preventing skeletal
muscle deterioration during a SECOPD may result in the
improvement of these outcomes and facilitate the success
of early PR programmes.
COPD patients admitted to hospital with a SECOPD are
severely limited by dyspnoea which precludes the initiation
of a conventional PR programme. Thus, strategies avoiding
respiratory system stress are needed. NMES increases
muscle strength in COPD patients with a very low metabolic
response incurring minimal stress to the respiratory
system.14,17
Interestingly, in our group of patients, a short NMES
programme, aimed at preventing skeletal muscle function
deterioration during SECOPD, not only prevented the
deterioration of muscle function, but significantly improved
muscle strength in the stimulated legs in comparison with
control legs. Moreover, all the patients tolerated the NMES
without any adverse effects and were capable of self-
administering the treatment. NMES therefore represents
a treatment to prevent muscle derangement during
a SECOPD prior to a post exacerbation PR programme which
may improve the success of subsequent PR.-60 -30 0 30 60
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NMES in severe COPD exacerbations 1433Other strategies have also been successful to prevent
deterioration of skeletal muscle function during hospital-
isation in COPD patients. Troosters et al.20 successfully used
a bench resistance training programme during a SECOPD to
train quadriceps muscles during hospital admissions (8
days). However, such a programme need to be administered
in hospital20 and requires trained personnel to be provided
and cannot be implemented as a self e administered
strategy. Another pilot study in patients with COPD
admitted to an ICU unit showed that a six weeks NMES
programme starting in the ICU and continuing in an in-
patient unit was successful to prevent skeletal muscle
function deterioration in 9 COPD patients.15 By contrast, we
have shown that, a short NMES programme aimed at pre-
venting further muscle function deterioration in patients
admitted to a general ward can produce similar effects
without the need for direct supervision and can be used as
a self-administered home based treatment, facilitating the
implementation of early discharge programmes and may
constitute a measure to compliment early post-
exacerbation PR.
Interestingly, we found a direct relationship between
the effect of the program (gain in QMVC) and the estimated
intensity of stimulation (
P
mA). This is not surprising and
confirms previous findings showing a direct relationship
between training intensity and improvement of out-
comes.21e23 It is of note that patients included in the
present study were encouraged to increase the intensity
(mA) of the training throughout the treatment period. The
intensity of the NMES stimulation depends greatly on
patient tolerance and adherence to the programme. In line
with previous reports,14,16 our programme was very well
tolerated and the patients were able to successfully
increase the training stimulation intensity (Fig. 2D). It is,
thus, mandatory to reassure the adherence and compliance
of the patients with the NMES programme to guarantee its
effects. This was achieved by simple measurements such as
telephone follow-up and a diary to collect information on
the intensity achieved in each session. To guarantee the
effectiveness of the programme, extra supervised sessions
at the patient’s home were added if needed. The adher-
ence and compliance with the programme was very good in
this group of patients as reflected by the measurements of
the battery power of each device before and after the
period of 14 days of NMES. It is worthwhile mentioning,
however, that we found that the rate of stimulation energy
increment was lower among the female population of the
study. This can be attributed to the lower electrical stim-
ulation pain threshold previously described in female
patients receiving NMES.24 In fact we found that women
trained with an overall reduced energy intensity (Fig. 2D)
and subjectively less muscle contraction than males. This
could, to some extent, explain the difference in the NMES
effect between genders.Limitations of the study
A potential caveat of the study was the absence of a sham
control leg as an unbiased control, but the fact that the
patients were allowed to control the intensity of stimula-
tion (power control based on pain tolerance) together withthe use of different protocols in each leg, made the
implementation of sham stimulation unviable.
The relatively small number of subjects constitutes
a potential limitation of the study. The novelty of the study
made difficult the calculation of a sample size in advance.
However, significant results were found despite the rela-
tively small population and the retrospectively calculated
statistical power of the primary outcome (improvement in
QMVC force) was 80%. The results of this pilot study needs
to be reproduced in a larger clinical trial. The results of this
pilot study constitute highly valuable information for the
design of such a trial.
Lastly, we have used a muscle measurement technique
that depends on the subject effort. However, this voluntary
contraction technique has been extensively used before
and showed a good correlation with less volitional methods
such us magnetic stimulation technique.25 It can be argued
that the QMVC manoeuvre is biased by the fact that the
patients know which leg is being stimulated. However, the
high correlation between the intensity of NMES and the
improvement of muscle strength in the stimulated leg
together with the absolute lack of such an association in the
non stimulated leg contradicts this argument.
Conclusion
This pilot study shows that a short NMES programme aimed
at preventing further muscle weakness development in
COPD patients admitted to a general ward due to a SECOPD
is feasible and effective to prevent skeletal muscle function
deterioration associated with exacerbations of the disease.
NMES may constitute a measure to compliment early post-
exacerbation PR programmes. These findings need to be
reproduced in a larger clinical trial.
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